SEC Comment Letter for Aptevo Therapeutics Inc. (APVO) (CIK 0001671584) (APVO) — Feb 11, 2019
Aptevo Therapeutics Inc. (APVO) (CIK 0001671584)
Date: Feb. 11, 2019 · CIK: 0001671584 · Accession: 0000000000-19-001761
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229115
Letter
February 8, 2019 Jeffrey Lamothe Chief Financial Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Re:Aptevo Therapeutics Inc. Registration Statement on Form S-3 Filed January 2, 2019 File No. 333-229115 Dear Mr. Lamothe : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Todd Schiffman at 202-551-3491 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
February 8, 2019
Jeffrey Lamothe
Chief Financial Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121
Re:Aptevo Therapeutics Inc.
Registration Statement on Form S-3
Filed January 2, 2019
File No. 333-229115
Dear Mr. Lamothe :
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Todd Schiffman at 202-551-3491 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance